AU2015276699B2 - Pyridino[1,2-a]pyrimidone analogue used as PI3K inhibitor - Google Patents

Pyridino[1,2-a]pyrimidone analogue used as PI3K inhibitor Download PDF

Info

Publication number
AU2015276699B2
AU2015276699B2 AU2015276699A AU2015276699A AU2015276699B2 AU 2015276699 B2 AU2015276699 B2 AU 2015276699B2 AU 2015276699 A AU2015276699 A AU 2015276699A AU 2015276699 A AU2015276699 A AU 2015276699A AU 2015276699 B2 AU2015276699 B2 AU 2015276699B2
Authority
AU
Australia
Prior art keywords
group
alkyl
pharmaceutically acceptable
compound
reaction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2015276699A
Other languages
English (en)
Other versions
AU2015276699A1 (en
Inventor
Shuhui Chen
Chengde Wu
Tao Yu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Original Assignee
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54934872&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2015276699(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from CN201410271282.9A external-priority patent/CN105461711B/zh
Application filed by Chia Tai Tianqing Pharmaceutical Group Co Ltd filed Critical Chia Tai Tianqing Pharmaceutical Group Co Ltd
Publication of AU2015276699A1 publication Critical patent/AU2015276699A1/en
Application granted granted Critical
Publication of AU2015276699B2 publication Critical patent/AU2015276699B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU2015276699A 2014-06-17 2015-06-16 Pyridino[1,2-a]pyrimidone analogue used as PI3K inhibitor Active AU2015276699B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201410271282.9A CN105461711B (zh) 2014-06-17 2014-06-17 作为PI3K抑制剂的吡啶并[1,2-a]嘧啶酮类似物
CN201410271282.9 2014-06-17
CN201510324348 2015-06-12
CN201510324348.0 2015-06-12
PCT/CN2015/081518 WO2015192760A1 (zh) 2014-06-17 2015-06-16 作为pi3k抑制剂的吡啶并［1，2-a］嘧啶酮类似物

Publications (2)

Publication Number Publication Date
AU2015276699A1 AU2015276699A1 (en) 2017-01-19
AU2015276699B2 true AU2015276699B2 (en) 2019-10-10

Family

ID=54934872

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015276699A Active AU2015276699B2 (en) 2014-06-17 2015-06-16 Pyridino[1,2-a]pyrimidone analogue used as PI3K inhibitor

Country Status (11)

Country Link
US (1) US9856256B2 (enExample)
EP (1) EP3159341B8 (enExample)
JP (1) JP6680774B2 (enExample)
KR (1) KR102495840B1 (enExample)
CN (1) CN106470992B (enExample)
AU (1) AU2015276699B2 (enExample)
CA (1) CA2951971C (enExample)
EA (1) EA032642B1 (enExample)
ES (1) ES2754264T3 (enExample)
TW (1) TWI628180B (enExample)
WO (1) WO2015192760A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3395817T3 (pl) * 2015-12-16 2022-05-02 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Analog pirydo[1,2-a]pirymidonu, jego krystaliczna postać, jego związek pośredni i sposób jego wytwarzania
CN110386932A (zh) * 2018-04-20 2019-10-29 艾科思莱德制药公司 用于抗肿瘤疗法中的双重atm和dna-pk抑制剂
US12325695B2 (en) * 2019-01-24 2025-06-10 Jiangsu Aosaikang Pharmaceutical Co., Ltd. 5-(4-pyridyloxy)pyrazole compounds serving as TGF-βR1 kinase inhibitor
CN115151540A (zh) 2019-12-02 2022-10-04 风暴治疗有限公司 作为mettl3抑制剂的多杂环化合物
CN115003674A (zh) 2020-02-10 2022-09-02 正大天晴药业集团股份有限公司 吡啶并[1,2-a]嘧啶酮化合物的治疗淋巴瘤的用途
WO2021180111A1 (zh) 2020-03-10 2021-09-16 正大天晴药业集团股份有限公司 包括吡啶并[1,2-a]嘧啶酮化合物的药物组合
WO2022057812A1 (zh) 2020-09-15 2022-03-24 正大天晴药业集团股份有限公司 吡啶并[1,2-a]嘧啶酮化合物的治疗外周T细胞淋巴瘤的用途
WO2022121929A1 (zh) * 2020-12-08 2022-06-16 正大天晴药业集团股份有限公司 吡啶并[1,2-a]嘧啶酮化合物的治疗妇科肿瘤的用途
WO2023169488A1 (zh) * 2022-03-09 2023-09-14 正大天晴药业集团股份有限公司 包括吡啶并[1,2-a]嘧啶酮化合物和EGFR抑制剂的药物组合

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014022128A1 (en) * 2012-07-29 2014-02-06 Calitor Sciences, Llc Pi3 kinase modulators and methods of use
WO2014110297A1 (en) * 2013-01-09 2014-07-17 Gilead Sciences, Inc. (hetero) arylacetamide derivatives as antiretroviral agents

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0415185A (pt) * 2003-10-10 2006-11-28 Pfizer Prod Inc 2h-[1,2,4]triazol[4,3-a]pirazinas substituìdas como inibidores da gsk-3
EP2038272B8 (en) * 2006-06-30 2013-10-23 Sunesis Pharmaceuticals, Inc. Pyridinonyl pdk1 inhibitors
EP2211615A4 (en) * 2007-10-22 2010-10-13 Glaxosmithkline Llc PYRIDOSULFONAMIDE DERIVATIVES AS PI3 KINASE INHIBITORS
CA2725014C (en) * 2008-05-30 2014-06-17 Amgen Inc. Inhibitors of pi3 kinase
EP2588197B1 (en) * 2010-07-02 2014-11-05 Gilead Sciences, Inc. Fused heterocyclic compounds as ion channel modulators
WO2012037108A1 (en) * 2010-09-13 2012-03-22 Glaxosmithkline Llc Aminoquinoline derivatives as antiviral agents
WO2013071698A1 (zh) * 2011-11-17 2013-05-23 山东轩竹医药科技有限公司 三环类PI3K和/或mTOR抑制剂
CN103539777B (zh) 2012-07-13 2016-03-02 广东东阳光药业有限公司 Pi3激酶调节剂及其使用方法和用途
WO2015192761A1 (zh) * 2014-06-17 2015-12-23 辰欣药业股份有限公司 作为mTOR/PI3K抑制剂的吡啶并[1,2-a]嘧啶酮类似物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014022128A1 (en) * 2012-07-29 2014-02-06 Calitor Sciences, Llc Pi3 kinase modulators and methods of use
WO2014110297A1 (en) * 2013-01-09 2014-07-17 Gilead Sciences, Inc. (hetero) arylacetamide derivatives as antiretroviral agents

Also Published As

Publication number Publication date
KR20170016465A (ko) 2017-02-13
CA2951971C (en) 2024-09-10
US9856256B2 (en) 2018-01-02
CN106470992A (zh) 2017-03-01
EA201790016A1 (ru) 2017-06-30
KR102495840B1 (ko) 2023-02-03
ES2754264T3 (es) 2020-04-16
EA032642B1 (ru) 2019-06-28
JP2017519821A (ja) 2017-07-20
CN106470992B (zh) 2018-11-06
AU2015276699A1 (en) 2017-01-19
TWI628180B (zh) 2018-07-01
WO2015192760A1 (zh) 2015-12-23
EP3159341B8 (en) 2020-01-08
EP3159341B1 (en) 2019-08-21
CA2951971A1 (en) 2015-12-23
TW201625612A (zh) 2016-07-16
EP3159341A4 (en) 2018-05-16
EP3159341A1 (en) 2017-04-26
US20170137420A1 (en) 2017-05-18
JP6680774B2 (ja) 2020-04-15

Similar Documents

Publication Publication Date Title
AU2015276699B2 (en) Pyridino[1,2-a]pyrimidone analogue used as PI3K inhibitor
US10093656B2 (en) Fused-ring or tricyclic aryl pyrimidine compound used as kinase inhibitor
EP3159342B1 (en) Pyridino[1,2-a]pyrimidone analogue used as mtor/pi3k inhibitor
AU2021208025A1 (en) Pyrimidine-4(3H)-ketone heterocyclic compound, preparation method therefor and use thereof in medicine and pharmacology
TWI694998B (zh) Jak抑制劑
WO2014100540A1 (en) Pyrazole substituted imidazopyrazines as casein kinase 1 d/e inhibitors
KR20230104782A (ko) Bcr-abl 티로신 키나제 억제용 7-아자인돌 화합물
KR20230074733A (ko) Myc 패밀리 원종양유전자 단백질의 조정제
KR102682398B1 (ko) 다이아실글리세롤 키나아제 저해제로서 헤테로사이클 화합물 및 이의 용도
JP2022515309A (ja) 置換アリール化合物、その製造方法及び用途
TW202204351A (zh) 具有大環結構的化合物及其用途
CN118976029A (zh) 用于预防或治疗帕金森病或非酒精性脂肪性肝炎的药学组合物
CN114907350B (zh) 一类含氮稠环类化合物、制备方法和用途
US20260125346A1 (en) Isoquinolinone Derivatives and 4H-Quinolizinone Derivatives and Pharmaceutical Compositions Thereof for the Treatment of Disease
KR20250121126A (ko) Irak3의 리간드 지정 분해제로서의 치환된 이미다조-기재 화합물
HK40002986A (zh) 吡啶并嘧啶酮cdk2/4/6抑制剂

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)